NAD+

Nicotinamide adenine dinucleotide (NAD+) is a redox cofactor used by more than 500 enzymes in the human body. It cycles between an oxidized form (NAD+) and a reduced form (NADH), accepting and donating electrons in glycolysis, the citric acid cycle, fatty acid oxidation, and the mitochondrial electron transport chain. It is also the substrate consumed by three families of enzymes that have become central to aging research: sirtuins, PARPs, and CD38.

NAD+ was first isolated by Arthur Harden and William Young in 1906. They called it cozymase. Otto Warburg established its redox function in the 1930s. Hans Krebs and Albert Lehninger mapped its central role in metabolism in the 1940s and 1950s. None of that classical biochemistry implied that NAD+ would become a longevity supplement target. That happened almost a century later, with two threads of research.

The Aging Connection

In 2003, David Sinclair's lab at Harvard reported that resveratrol activated SIRT1, a yeast sirtuin homolog in mammals, and that sirtuin activation depended on NAD+. The mouse experiments that followed, particularly Yoshino, Mills, and Imai's work on NMN, demonstrated that boosting NAD+ levels in old mice produced metabolic, muscular, and vascular improvements that looked like a partial reversal of aging phenotypes. Lifespan extension in rodents was modest but reproducible across several labs.

Whether the same translates to humans is the unresolved question. NAD+ levels do decline with age, but the decline is tissue-specific. Massudi et al. (2012) showed a decline in human skin with age. Zhou et al. (2016) showed it in liver. Zhu et al. (2015) showed it in brain. Other tissues do not. The decline appears to be driven less by reduced synthesis and more by increased consumption: CD38, an NADase on senescent immune cells, increases with age and degrades NAD+ extracellularly.

The Human Trials Problem

Over a dozen randomized human trials have tested NAD+ precursors, mainly NR and NMN, in healthy adults and in specific patient populations. Most show that the precursors are safe and that they raise circulating NAD+ to varying degrees. Functional benefits are harder to document.

The benchmark trial for NR is Martens et al., Nature Communications 2018, a crossover study in healthy middle-aged and older adults. Six weeks of 500 mg twice daily raised whole-blood NAD+ by approximately 60 percent. Exploratory cardiovascular endpoints suggested possible reductions in systolic blood pressure and arterial stiffness in participants with elevated baseline values, but the trial was not powered for those endpoints.

The benchmark trial for NMN is Yoshino et al., Science 2021, in prediabetic postmenopausal women. Ten weeks of 250 mg per day improved muscle insulin sensitivity. The effect was modest, the cohort was specific, and the trial was small (25 patients per arm).

The 2026 head-to-head trial is Christen et al., Nature Metabolism. Sixty-five healthy adults were randomized to 1,000 mg per day of NMN, NR, plain nicotinamide, or placebo for 14 days. NMN and NR both approximately doubled circulating NAD+. Nicotinamide did not. There was no measurable difference between NMN and NR on the primary biomarker endpoint.

The Vinten et al. October 2025 review in Nature Metabolism aggregated this body of evidence and concluded that preclinical NAD+ supplementation strategies have not yet translated into demonstrated efficacy in human aging trials. Areas with the most signal are neurodegeneration, vision, hearing, and inflammation. Areas with the least signal are musculoskeletal function and broad aging biomarkers.

Regulatory and Legal Status

NAD+ itself is not regulated as a drug. The molecule occurs naturally and is not subject to a separate approval pathway.

The precursors have a more complicated history. Nicotinamide riboside (NR), sold most prominently as Niagen by ChromaDex, received FDA GRAS (Generally Recognized As Safe) status in 2015 and has been continuously available as a dietary supplement in the US since then.

Nicotinamide mononucleotide (NMN) had a regulatory crisis. In late 2022, the FDA stated that NMN was excluded from the dietary supplement category under the DSHEA "drug preclusion" rule, because Metro International Biotech had filed an Investigational New Drug (IND) application for NMN as a pharmaceutical. NMN sales continued anyway. In September 2025, the FDA reversed that position and confirmed that NMN qualifies as a dietary supplement.

IV NAD+ infusions are administered in wellness clinics, longevity practices, and addiction-recovery centers. The doses range from 200 mg to over 1,000 mg per session, infused over 1 to 4 hours, often over consecutive days. No IV NAD+ product is FDA-approved to treat any disease. The FDA has periodically reminded compounding pharmacies about appropriate sterile-ingredient sourcing for IV preparations, but has not banned the practice.

NAD+ and its precursors are not on the WADA Prohibited List. They are not restricted in sport.

NAD+ is a small dinucleotide consisting of two nucleotides joined by phosphate groups: one nucleotide contains adenine, the other contains nicotinamide. Molecular weight is 663.4 g/mol. It functions in two distinct roles in the cell.

The first role is redox cofactor. In glycolysis and the citric acid cycle, NAD+ accepts electrons (becoming NADH) and ferries them to the inner mitochondrial membrane, where Complex I of the electron transport chain strips them off and uses the energy to pump protons. This is the route by which the calories in glucose and fatty acids are converted to ATP. The redox role is unchanged across all eukaryotes and most prokaryotes.

The second role is substrate for NAD+-consuming enzymes, and this is the role that drives the longevity story. Three enzyme families consume NAD+:

The sirtuins (SIRT1 through SIRT7) are deacetylases that remove acetyl groups from histones and other proteins, cleaving NAD+ in the process. Sirtuin activity affects gene expression, mitochondrial biogenesis, DNA repair, and cellular stress response. Sinclair's work positioned sirtuin activation as the central mechanism by which NAD+ might affect aging.

The PARPs (poly-ADP-ribose polymerases), particularly PARP1, are activated by DNA damage. They use NAD+ to attach poly-ADP-ribose chains to damaged DNA and to repair machinery. Chronic genomic damage with age means chronic PARP activation, which drains NAD+ pools.

The CD38 ecto-NADase is a glycohydrolase on immune cells. CD38 expression increases on senescent immune cells in older tissues. The enzyme degrades NAD+ extracellularly with low Km. CD38 inhibitors are an active drug-discovery target precisely because slowing CD38 could preserve NAD+ better than supplementing precursors.

The biosynthesis of NAD+ uses three pathways. The de novo pathway from tryptophan makes NAD+ from scratch but is metabolically expensive and contributes a minority of cellular NAD+. The Preiss-Handler pathway from nicotinic acid (niacin) feeds in through nicotinic acid mononucleotide. The salvage pathway from nicotinamide (the most active route in most cells) uses NAMPT (nicotinamide phosphoribosyltransferase) as the rate-limiting enzyme. NR feeds the salvage pathway through nicotinamide riboside kinase. NMN feeds it one step downstream of NR.

NAD+ itself cannot efficiently cross the cell membrane. That is why oral NAD+ tablets are mechanistically weak. Precursors work because they cross the membrane (or are converted to species that do) before being assembled into NAD+ inside the cell.

In humans, supplementation with NR or NMN reliably raises blood NAD+ and its related metabolites. That biomarker outcome is the most consistent finding across more than 30 published trials.

Functional outcomes are far less consistent. Reported endpoints across published trials include:

• Cardiovascular: Martens 2018 suggested reductions in systolic blood pressure and arterial stiffness, particularly in participants with elevated baseline values. The signal is preliminary.
• Insulin sensitivity: Yoshino 2021 in prediabetic women, modest improvement at 250 mg NMN per day.
• Muscle function and exercise recovery: mixed results across small trials. Some show improvements in fatigue and time-to-exhaustion, others show no benefit.
• Cognition: animal models are positive, particularly in Alzheimer's mouse models (Hou et al., 2018). Human trials have not consistently replicated this.
• Inflammation: NAD+ infusions in commercial settings report subjective improvements in fatigue and well-being. None has been validated in a placebo-controlled outcome.

The Vinten 2025 review identified neurodegeneration, vision, hearing, and inflammation as the clinical areas with the most promising signal. Musculoskeletal conditions appear less receptive. Broad anti-aging claims remain unsupported by controlled outcomes.

Oral NR doses in published trials range from 100 mg to 2,000 mg per day. Doses of 300 mg per day produce a 40 to 60 percent rise in blood NAD+ over 8 weeks. Doses of 1,000 mg per day approximately double NAD+ within 14 days. NR is most commonly taken as a once-daily morning dose, although split dosing (250 mg twice daily) appears equivalent in pharmacokinetic studies.

Oral NMN doses in published trials range from 150 mg to 1,250 mg per day. The Yoshino 2021 Science trial used 250 mg per day. The Christen 2026 head-to-head used 1,000 mg per day. Sub-lingual and buccal NMN delivery have been marketed but are not better-supported by controlled pharmacokinetic data than oral capsules.

IV NAD+ is given in 200-1,000 mg sessions over 1 to 4 hours, often over consecutive days. The retrospective real-world pilot (linked above) used 500 mg IV NAD+ or 500 mg IV NR daily for 4 days. IV infusion bypasses the gut and any first-pass metabolism issues, but it requires clinical administration and produces a transient surge rather than a sustained tissue elevation.

Subcutaneous NAD+ at 100-500 mg per day is sold by some compounding pharmacies. Pharmacokinetic data on this route in humans is sparse. The mechanistic argument is that SC NAD+ provides similar bioavailability to IV without the chair time. The supporting trials do not exist.

The methyl donor caveat matters at high doses. NAD+ metabolism consumes methyl groups via nicotinamide N-methyltransferase (NNMT), which converts nicotinamide to N-methyl-nicotinamide using S-adenosyl-methionine (SAM). Long-term high-dose NR or NMN may deplete SAM and downstream methyl-dependent reactions. The practical recommendation that circulates is to co-supplement with TMG (trimethylglycine, also called betaine) at 500-1,000 mg per day. The empirical evidence for this is weak. The mechanistic argument is reasonable.

NAD+ precursors are among the best-tolerated longevity interventions in clinical trial data. Across more than two dozen published trials with NR and NMN, the most commonly reported adverse effects are mild gastrointestinal symptoms (nausea, abdominal discomfort, diarrhea), particularly at higher doses (>1,000 mg per day).

Some users report flushing with high-dose oral nicotinamide (the active end-metabolite of both NR and NMN), though it is less pronounced than the flushing that comes with nicotinic acid (niacin). Skin flushing reflects prostaglandin D2 release and is dose-dependent.

IV NAD+ has a distinctive infusion-related side effect profile. Patients commonly report chest pressure, nausea, anxiety, and a "tight" sensation during infusion, particularly when the rate is too fast. Slowing the drip generally resolves these. Post-infusion fatigue lasting 24 to 48 hours is reported. The retrospective pilot of 500 mg IV NAD+ versus 500 mg IV NR found that IV NR had a faster, better-tolerated infusion profile than IV NAD+.

Theoretical concerns at chronic high doses include methyl donor depletion, potential effects on cancer biology (NAD+ supports proliferation of dividing cells, including malignant ones), and unknown long-term consequences of sustained elevation outside the normal physiological range. None of these has produced documented harm in trials of up to 2 years.

NAD+ supplementation is not recommended during active cancer treatment without oncologist input. The biology around NAD+ and tumor growth is genuinely complex, with NAD+ both supporting and limiting tumor proliferation depending on context.

NAD+ precursors are often paired with mitochondrial-targeting compounds. The pairing with SS-31 is mechanistically distinct: SS-31 stabilizes cardiolipin and improves electron-transport-chain efficiency, while NAD+ provides the substrate that the ETC requires. The pairing with MOTS-c addresses mitochondrial regulatory signaling. The pairing with methylene blue is mechanistically complementary: methylene blue shuttles electrons past damaged ETC complexes, while NAD+ supplies them.

The pairing with resveratrol is the original Sinclair-protocol stack: resveratrol activates SIRT1, NAD+ is the sirtuin substrate. The human evidence that this combination outperforms either alone is, like most NAD+ functional claims, not from controlled trials.

The pairing with TMG (trimethylglycine) is intended to offset methyl donor consumption at high NMN or NR doses. Mechanistically reasonable, empirically untested.

The pairing NAD+ precursors should be approached carefully with is PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib), which are used in some cancer treatment regimens. PARP inhibitors block one of the NAD+ consumers; co-supplementing the substrate is a poorly characterized interaction and any patient on these drugs should consult their oncologist before adding NAD+ or its precursors.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.